Our Pipeline

Central Nervous System Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrolling

Mid-Phase III

TNX-102 SL   Posttraumatic Stress Disorder (PTSD)
Phase II start — targeting 4Q 2022

Phase II

TNX-102 SL   Long COVID
Phase II start — PREVAIL study enrolling

Phase II

TNX-601 ER   Depression, PTSD, Neurocognitive Dysfunction from Corticosteroids
Phase II start — targeting 1Q 2023

Phase I

TNX-1300   Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation

Mid-Phase II

TNX-1900   Chronic Migraine
Phase II start — targeting 4Q 2022

Phase II

Immunology Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I start — targeting 1H 2023

Preclinical

TNX-1700  Gastric and Colorectal Cancers

Preclinical

Infectious Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Long COVID
Phase II start — PREVAIL study enrolling

Phase II

TNX-1850   COVID-19 Vaccine
Preclinical

Preclinical

TNX-801  Smallpox and Monkeypox Preventing Vaccine
Phase I start — targeting 1H 2023

Preclinical

Rare Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-2900   Prader-Willi Syndrome
FDA Orphan Drug Designation

Preclinical